Q-omics provides the consensus-scored GOLGA6C profile across patient tissues and cancer cell-line models. GOLGA6C expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, GOLGA6C is differentially expressed in 1, with the highest sampling consensus in LIHC. Additionally, GOLGA6C RNA expression shows 6,805 significant gene co-expression associations, with the highest sampling consensus in SCLC. Together, these results highlight ESCA, LIHC, and SCLC as cancer lineages where GOLGA6C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GOLGA6C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GOLGA6C survival associations across molecular data types. GOLGA6C RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GOLGA6C RNA expression–survival associations across cancer types. High GOLGA6C expression shows unfavorable associations in ESCA, HNSC, KIRC, COAD, KICH and UCS. The ESCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ESCA as the clearest survival context for GOLGA6C RNA expression.
This table summarizes GOLGA6C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for GOLGA6C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GOLGA6C shows higher tumor expression in LIHC. The LIHC box plot shows higher GOLGA6C RNA expression in tumor versus normal tissue (log2 FC = +0.025, t-test p = .024).
This table shows molecular features associated with GOLGA6C in patient tissues and cancer cell lines. In patient samples, GOLGA6C shows the broadest associations at the RNA and protein expression levels, with SCLC recurring as the lineage with the largest associated feature set. In cancer cell lines, GOLGA6C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BREAST.
